According to Nova one advisor, the global Generic Injectable Market Size was valued at USD 95.3 billion in 2022 and is predicted to be worth USD 340.1 billion by 2032, with a CAGR of 15.58% from 2023 to 2032.
Key Takeaway:
Generic Injectables Market: Overview
Report Scope of the Generic Injectable Market
Report Coverage |
Details |
Market Size in 2023 |
USD 98.19 Billion |
Market Size by 2032 |
USD 340.1 Billion |
Growth Rate from 2023 to 2032 |
CAGR of 15.58% |
Base Year |
2022 |
Forecast Period |
2023 to 2032 |
Segments Covered |
Product Type, Molecular Type, Application, Administration, Distribution Channel and Geography |
Challenges Posed by Syringe Inspection Affect Market Growth
Syringes are among the most difficult containers to inspect. With the largest vaccination effort in human history, challenges posed by syringe inspection become especially relevant while considering the ever-growing adoption of injectable drugs. These findings have led to the need of sophisticated inspection systems to help manufacturers address not only the coronavirus pandemic but also various other maladies.
While other containers such as cartridges, vials, and ampoules largely stand still and can enter the inspection process independently, syringes are typically carried via conveyor and then turned upside down. This has resulted in the need for robust inspection systems so that any hidden particles in the funnel can sink down into the liquid for increased inspection detectability.
Manufacturers Expand Revenue Streams in Routine, Complex Injectable Products
The global generic injectables market is projected to clock a CAGR of 15.58% during the forecast period. Biological E Limited - an Indian biotechnology and biopharmaceutical company based in Hyderabad, Telangana, is gaining recognition for broadening its portfolio in 20 routine and complex injectable products. In order to establish stable revenue streams, companies are tapping into regulated markets and exploring other markets to generate income sources.
There is a growing demand for specialty generic injectables packaged in glass vials. Express Pharma in associated with West Pharma recently conducted a webinar to understand why emerging generic injectable manufacturers need flexibility and simplicity when dealing with drug delivery and containment.
Product Type Insight
Monoclonal antibodies to hold the highest market share with increased revenue during the forecast period of generic injectables.
Molecule Type Insight
Increased research and development in large molecules for developing the generic injectables with increased opportunity and increased share in the market.
Which helps to increase the market of generic injectables. However, the small molecule segment is poised to grow at a higher CAGR during the forecast period 2023 to 2032.
Application Insight
Increased growth of the diabetes disease with increased life style and dietary supplements with high rate of patients among the population due to the previous family or increased obesity. Which led to increase of the diabetes with increased demand for the generic injectables. Oncology is also rising from the year 2021 with increased chemotherapies and generic injectables with high demand for the medication from the health care centre. However, the diabetes segment is growing at the strongest CAGR from 2023 to 2032.
Distribution Channel Insight
Segmentation of generic injectables based on distribution channel involves Hospital pharmacy, retail pharmacy, drug stores and online pharmacy. Due to increased chronic infectious diseases with enlargement of the hospitals with their own hospital pharmacy increase growth of the hospital across the regions. Hospital pharmacy to hold the largest market.
Generic Injectables Market: Regional
Segmentation of generic injectables based on geography sector North America to be the leading region with highest market growth of the generic injectables with increased development of the generic injectables with increased research and development from the key market players for introducing the generic injectables with increased demand from the health care center due to shortage of the injectable with increased chronic infectious diseases among the population with increased hospitalization rate of the patients.
Asia pacific region also helps to boost the market growth with increased demand from the health care centre for generic injectables with increased chronic diseases increasing due to rising population. Other regions such as Europe, Latin America, Middle East and Africa contributes to increase the market of generic injectables to a larger extend.
Recent Developments
Some of the prominent players in the Generic Injectable Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Generic Injectable market.
By Product Type
By Molecular Type
By Application
By Administration
By Distribution Channel
By Geography
Key Benefits for Stakeholders
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Generic Injectable Market
5.1. COVID-19 Landscape: Generic Injectable Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Generic Injectable Market, By Product Type
8.1. Generic Injectable Market, by Product Type, 2023-2032
8.1.1. Chemotherapy agents
8.1.1.1. Market Revenue and Forecast (2018-2032)
8.1.2. Small molecule antibiotics
8.1.2.1. Market Revenue and Forecast (2018-2032)
8.1.3. Vaccines
8.1.3.1. Market Revenue and Forecast (2018-2032)
8.1.4. Peptide antibiotics
8.1.4.1. Market Revenue and Forecast (2018-2032)
8.1.5. Blood factors
8.1.5.1. Market Revenue and Forecast (2018-2032)
8.1.6. Peptide hormone
8.1.6.1. Market Revenue and Forecast (2018-2032)
8.1.7. Insulin
8.1.7.1. Market Revenue and Forecast (2018-2032)
8.1.8. Cytokines
8.1.8.1. Market Revenue and Forecast (2018-2032)
8.1.9. Immunoglobin
8.1.9.1. Market Revenue and Forecast (2018-2032)
8.1.10. Monoclonal Antibodies
8.1.10.1. Market Revenue and Forecast (2018-2032)
Chapter 9. Global Generic Injectable Market, By Molecular Type
9.1. Generic Injectable Market, by Molecular Type, 2023-2032
9.1.1. Small Molecule
9.1.1.1. Market Revenue and Forecast (2018-2032)
9.1.2. Large Molecule
9.1.2.1. Market Revenue and Forecast (2018-2032)
Chapter 10. Global Generic Injectable Market, By Application
10.1. Generic Injectable Market, by Application, 2023-2032
10.1.1. Oncology
10.1.1.1. Market Revenue and Forecast (2018-2032)
10.1.2. Diabetes
10.1.2.1. Market Revenue and Forecast (2018-2032)
10.1.3. Infectious Diseases
10.1.3.1. Market Revenue and Forecast (2018-2032)
10.1.4. Blood Disorders
10.1.4.1. Market Revenue and Forecast (2018-2032)
10.1.5. Musculoskeletal Disorders
10.1.5.1. Market Revenue and Forecast (2018-2032)
10.1.6. Hormonal Disorders
10.1.6.1. Market Revenue and Forecast (2018-2032)
10.1.7. Pain Management
10.1.7.1. Market Revenue and Forecast (2018-2032)
10.1.8. CNS Diseases
10.1.8.1. Market Revenue and Forecast (2018-2032)
10.1.9. Cardiovascular Diseases
10.1.9.1. Market Revenue and Forecast (2018-2032)
Chapter 11. Global Generic Injectable Market, By Administration
11.1. Generic Injectable Market, by Administration, 2023-2032
11.1.1. Intravenous (IV)
11.1.1.1. Market Revenue and Forecast (2018-2032)
11.1.2. Intramuscular (IM)
11.1.2.1. Market Revenue and Forecast (2018-2032)
11.1.3. Intramuscular (IM)
11.1.3.1. Market Revenue and Forecast (2018-2032)
Chapter 12. Global Generic Injectable Market, By Distribution Channel
12.1. Generic Injectable Market, by Distribution Channel, 2023-2032
12.1.1. Hospital pharmacy
12.1.1.1. Market Revenue and Forecast (2018-2032)
12.1.2. Hospital pharmacy
12.1.2.1. Market Revenue and Forecast (2018-2032)
12.1.3. Drug stores
12.1.3.1. Market Revenue and Forecast (2018-2032)
12.1.4. Online pharmacy
12.1.4.1. Market Revenue and Forecast (2018-2032)
Chapter 13. Global Generic Injectable Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Product Type (2018-2032)
13.1.2. Market Revenue and Forecast, by Molecular Type (2018-2032)
13.1.3. Market Revenue and Forecast, by Application (2018-2032)
13.1.4. Market Revenue and Forecast, by Administration (2018-2032)
13.1.5. Market Revenue and Forecast, by Distribution Channel (2018-2032)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Product Type (2018-2032)
13.1.6.2. Market Revenue and Forecast, by Molecular Type (2018-2032)
13.1.6.3. Market Revenue and Forecast, by Application (2018-2032)
13.1.6.4. Market Revenue and Forecast, by Administration (2018-2032)
13.1.6.5. Market Revenue and Forecast, by Distribution Channel (2018-2032)
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Product Type (2018-2032)
13.1.7.2. Market Revenue and Forecast, by Molecular Type (2018-2032)
13.1.7.3. Market Revenue and Forecast, by Application (2018-2032)
13.1.7.4. Market Revenue and Forecast, by Administration (2018-2032)
13.1.7.5. Market Revenue and Forecast, by Distribution Channel (2018-2032)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Product Type (2018-2032)
13.2.2. Market Revenue and Forecast, by Molecular Type (2018-2032)
13.2.3. Market Revenue and Forecast, by Application (2018-2032)
13.2.4. Market Revenue and Forecast, by Administration (2018-2032)
13.2.5. Market Revenue and Forecast, by Distribution Channel (2018-2032)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Product Type (2018-2032)
13.2.6.2. Market Revenue and Forecast, by Molecular Type (2018-2032)
13.2.6.3. Market Revenue and Forecast, by Application (2018-2032)
13.2.7. Market Revenue and Forecast, by Administration (2018-2032)
13.2.8. Market Revenue and Forecast, by Distribution Channel (2018-2032)
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Product Type (2018-2032)
13.2.9.2. Market Revenue and Forecast, by Molecular Type (2018-2032)
13.2.9.3. Market Revenue and Forecast, by Application (2018-2032)
13.2.10. Market Revenue and Forecast, by Administration (2018-2032)
13.2.11. Market Revenue and Forecast, by Distribution Channel (2018-2032)
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Product Type (2018-2032)
13.2.12.2. Market Revenue and Forecast, by Molecular Type (2018-2032)
13.2.12.3. Market Revenue and Forecast, by Application (2018-2032)
13.2.12.4. Market Revenue and Forecast, by Administration (2018-2032)
13.2.13. Market Revenue and Forecast, by Distribution Channel (2018-2032)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Product Type (2018-2032)
13.2.14.2. Market Revenue and Forecast, by Molecular Type (2018-2032)
13.2.14.3. Market Revenue and Forecast, by Application (2018-2032)
13.2.14.4. Market Revenue and Forecast, by Administration (2018-2032)
13.2.15. Market Revenue and Forecast, by Distribution Channel (2018-2032)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Product Type (2018-2032)
13.3.2. Market Revenue and Forecast, by Molecular Type (2018-2032)
13.3.3. Market Revenue and Forecast, by Application (2018-2032)
13.3.4. Market Revenue and Forecast, by Administration (2018-2032)
13.3.5. Market Revenue and Forecast, by Distribution Channel (2018-2032)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Product Type (2018-2032)
13.3.6.2. Market Revenue and Forecast, by Molecular Type (2018-2032)
13.3.6.3. Market Revenue and Forecast, by Application (2018-2032)
13.3.6.4. Market Revenue and Forecast, by Administration (2018-2032)
13.3.7. Market Revenue and Forecast, by Distribution Channel (2018-2032)
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Product Type (2018-2032)
13.3.8.2. Market Revenue and Forecast, by Molecular Type (2018-2032)
13.3.8.3. Market Revenue and Forecast, by Application (2018-2032)
13.3.8.4. Market Revenue and Forecast, by Administration (2018-2032)
13.3.9. Market Revenue and Forecast, by Distribution Channel (2018-2032)
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Product Type (2018-2032)
13.3.10.2. Market Revenue and Forecast, by Molecular Type (2018-2032)
13.3.10.3. Market Revenue and Forecast, by Application (2018-2032)
13.3.10.4. Market Revenue and Forecast, by Administration (2018-2032)
13.3.10.5. Market Revenue and Forecast, by Distribution Channel (2018-2032)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Product Type (2018-2032)
13.3.11.2. Market Revenue and Forecast, by Molecular Type (2018-2032)
13.3.11.3. Market Revenue and Forecast, by Application (2018-2032)
13.3.11.4. Market Revenue and Forecast, by Administration (2018-2032)
13.3.11.5. Market Revenue and Forecast, by Distribution Channel (2018-2032)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Product Type (2018-2032)
13.4.2. Market Revenue and Forecast, by Molecular Type (2018-2032)
13.4.3. Market Revenue and Forecast, by Application (2018-2032)
13.4.4. Market Revenue and Forecast, by Administration (2018-2032)
13.4.5. Market Revenue and Forecast, by Distribution Channel (2018-2032)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Product Type (2018-2032)
13.4.6.2. Market Revenue and Forecast, by Molecular Type (2018-2032)
13.4.6.3. Market Revenue and Forecast, by Application (2018-2032)
13.4.6.4. Market Revenue and Forecast, by Administration (2018-2032)
13.4.7. Market Revenue and Forecast, by Distribution Channel (2018-2032)
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Product Type (2018-2032)
13.4.8.2. Market Revenue and Forecast, by Molecular Type (2018-2032)
13.4.8.3. Market Revenue and Forecast, by Application (2018-2032)
13.4.8.4. Market Revenue and Forecast, by Administration (2018-2032)
13.4.9. Market Revenue and Forecast, by Distribution Channel (2018-2032)
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Product Type (2018-2032)
13.4.10.2. Market Revenue and Forecast, by Molecular Type (2018-2032)
13.4.10.3. Market Revenue and Forecast, by Application (2018-2032)
13.4.10.4. Market Revenue and Forecast, by Administration (2018-2032)
13.4.10.5. Market Revenue and Forecast, by Distribution Channel (2018-2032)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Product Type (2018-2032)
13.4.11.2. Market Revenue and Forecast, by Molecular Type (2018-2032)
13.4.11.3. Market Revenue and Forecast, by Application (2018-2032)
13.4.11.4. Market Revenue and Forecast, by Administration (2018-2032)
13.4.11.5. Market Revenue and Forecast, by Distribution Channel (2018-2032)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Product Type (2018-2032)
13.5.2. Market Revenue and Forecast, by Molecular Type (2018-2032)
13.5.3. Market Revenue and Forecast, by Application (2018-2032)
13.5.4. Market Revenue and Forecast, by Administration (2018-2032)
13.5.5. Market Revenue and Forecast, by Distribution Channel (2018-2032)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Product Type (2018-2032)
13.5.6.2. Market Revenue and Forecast, by Molecular Type (2018-2032)
13.5.6.3. Market Revenue and Forecast, by Application (2018-2032)
13.5.6.4. Market Revenue and Forecast, by Administration (2018-2032)
13.5.7. Market Revenue and Forecast, by Distribution Channel (2018-2032)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Product Type (2018-2032)
13.5.8.2. Market Revenue and Forecast, by Molecular Type (2018-2032)
13.5.8.3. Market Revenue and Forecast, by Application (2018-2032)
13.5.8.4. Market Revenue and Forecast, by Administration (2018-2032)
13.5.8.5. Market Revenue and Forecast, by Distribution Channel (2018-2032)
Chapter 14. Company Profiles
14.1. DR. Reddys Laboratries Ltd
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Baxter International
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Mylan N.A
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Teva Pharmaceuticals
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Teva Pharmaceuticals
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Sanofi S.A
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Fresenius Kabi
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Pfizer Inc
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Cipla Ltd
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Merck & Co. Inc
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms